Iontas is using Nav1.7, ASIC1a, and Kv1.3 channels as case studies, and Aneesh gave an overview of Kv1.3 as a target for autoimmune disease, which affects 2–3% of the worlds' population and may have a market value ∼$45.5 Bn by 2022. This evidence concerns the gene KCNA3 and autoimmune disease.